Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Luxna Biotech Co. Ltd. is currently managing 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 2 distinct examiners, which indicates that each pending case is being handled by a different individual. This lack of examiner overlap suggests that prosecution strategies should be tailored to the specific preferences of each official. The company must manage separate communication channels for each of the 2 pending office actions to address the unique concerns raised by the assigned staff.
The portfolio shows a specific technical concentration, as all activity is confined to 1 distinct art unit. This focus allows the applicant to develop familiarity with the specific examination standards and internal practices of that particular unit. Within this framework, PERSONS, JENNA L is identified as the busiest examiner for the company, currently overseeing 1 pending office action. This examiner is responsible for 1 of the active files, making their individual feedback a key component of the firm's current prosecution cycle.
Practitioners should note the balance between the pending workload and the 2 distinct examiners. Because the busiest examiner, PERSONS, JENNA L, is responsible for 1 pending action, the remaining workload is assigned to another official. This structure requires the applicant to maintain consistent arguments across the separate files while operating within the 1 distinct art unit that governs the portfolio. The strategy relies on navigating the requirements of two different examiners simultaneously.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| §112 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PERSONS, JENNA L | 1 | 50.8% | +61.7% |
| ZARA, JANE J | 1 | 71.0% | +16.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18558056 | METHOD FOR DESIGNING OLIGONUCLEOTIDE HAVING REDUCED CENTRAL TOXICITY | PERSONS, JENNA L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18035300 | Agent for Regulating Expression and/or Function of RPS25 Gene | ZARA, JANE J | 22d |
| 18558056 | METHOD FOR DESIGNING OLIGONUCLEOTIDE HAVING REDUCED CENTRAL TOXICITY | PERSONS, JENNA L | — |
| Art Unit | Apps |
|---|---|
| 1637 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18558056 | METHOD FOR DESIGNING OLIGONUCLEOTIDE HAVING REDUCED CENTRAL TOXICITY | PERSONS, JENNA L | 1637 | §101§102§103§112DP | Non-Final OA | — | Pending | Oct 30, 2023 |
| 18035300 | Agent for Regulating Expression and/or Function of RPS25 Gene | ZARA, JANE J | 1637 | §112 | Final Rejection | 22d | Pending | May 04, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialLuxna Biotech Co. Ltd. has 2 pending office actions as of October 2026, spread across 1 art units and 2 examiners.
Jenna L Persons has the most, with 1 of Luxna Biotech Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
